Skip to main content
OpenTrials

Clinical trial condition

Meningococcal Disease

Explore clinical trials studying Meningococcal Disease. Study availability and eligibility vary by location and protocol.

57 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Meningococcal Disease trial results

Completed

Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers

NCT01994629

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Dipartimento di Prevenzione S C Igiene e Sanita Pubblica Chiavari, ASL4 Chiavarese Regione Liguria Corso Dante 163, Italy
  • Ospedale Maggiore della Carita Novara, Corso Mazzini 18, Italy
  • ASL Sassari 1 Servizio Igiene Pubblica Sassari, Via Amendola 55, Italy
  • AOU Meyer Dip Scienze per la Salute della Donna e Bambino Florence, Viale Pieraccini 24, Italy
View Trial Details
Completed

Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

NCT01973218

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +7 more
Locations
  • 06 Kosin University Gospel Hospital 34, amnam-dong Seo-gu, Busan, South Korea
  • 05 YuKorea University Ansan Hospital 23, Jeokgeum-ro, Danwon-gu Ansan-si, Gyeonggi-do, South Korea
  • 04 Pusan National University Yangsan Hospital 20 Geumo-ro, Mulgeum-eup Yangsan, Gyeongsangnam-do, South Korea
  • 07 Seoul National University Bundang Hospital 82, Gumi-ro 173 Beon-gil Bundang-gu, Seongnam, South Korea
View Trial Details
Completed

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age

NCT01139021

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • amostatná ordinace praktického lékaře pro děti a dorost Jindřichův Hradec Hradec, Czechia
  • Dětské oddělení nemocnice Náchod Náchod, Czechia
  • Dětské oddělení nemocnice Pardubice Pardubice, Czechia
  • University of Tampere Medical School, Vaccine Research Center Tampere Biokatu 10, Pirkanmaa, Finland
View all 19 locations
View Trial Details
Completed

Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster or as a Two-dose Catch-up to Healthy Toddlers

NCT00847145

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Gram-Negative Bacterial Infections, +4 more
Locations
  • Altenburger Eisenstadt, Austria
  • Grässl Hall in Tirol, Austria
  • Häckel Kirchdorf, Austria
  • Prieler Neufeld A.d. Leitha, Austria
View all 59 locations
View Trial Details
Completed

Safety of MenACWY-CRM Vaccination in Adolescents

NCT01452464

Conditions
Bacterial Infections, Bacterial Infections and Mycoses, Central Nervous System Bacterial Infections, +12 more
Locations
  • Riverside Medical Center Campus, 10800 Magnolia Ave Riverside, California, United States
  • San Diego Medical Center Campus, 4647 Zion Ave 92120 San Diego, California, United States
  • Fontana Medical Center Campus Valley Annex, 16994 E. Valley Blvd., Fontana, California, United States
View Trial Details

Related conditions